Compare Dow Inc (DOW) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Illumina, Inc. — how do they compare? Dow Inc trades at $30 (market cap $21.85B), while Illumina, Inc. trades at $190.58 (market cap $28.93B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.62% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DOW | ILMN | |
|---|---|---|
Market Cap | $21.85B | $28.93B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $194.33 |
52-Week Low | $20.65 | $91.00 |
Enterprise Value | $37.62B | $30.32B |
Dividend Yield | 4.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.37, up 4.62% on the day, with a bullish technical signal from moving averages despite negative profitability metrics. The company reported a net loss of $2.62 billion for 2025, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Dow's inclusion in discussions about materials stocks benefiting from oil price spikes, while cash flow trends show improved net cash generation in 2025.
The outlook is mixed: analyst consensus suggests 19% upside to the $36.11 price target, but high P/E of 75.93 and negative margins pose valuation risks. Key opportunities include dividend payments and earnings beats, while risks involve sustained profitability challenges and rising debt-to-asset ratios nearing 30%.
Illumina (ILMN) trades at $190.05, showing strong momentum with a 43.7% gain year-to-date and recent earnings beats. The stock is technically bullish, trading near resistance at $191 with solid fundamentals including 19.42% net margins and robust cash flow. Recent leadership appointments and product launches like StrataMap Spatial Solution highlight ongoing innovation in genomics sequencing.
Outlook remains positive driven by sequencing demand and margin expansion, but risks include competitive pressure from Roche's new sequencer and China market weakness. Analyst consensus is bullish with 51% buy ratings, though the current price exceeds the $174.44 target, suggesting near-term valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
